Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism

Abstract

Studies on the association between microparticle expressing tissue factor (MP-TF) activity, FVIII activity (FVIII:C) and recurrent VTE yielded inconclusive results. We studied these associations in patients diagnosed with acute pulmonary embolism. Plasma levels of MP-TF and FVIII activity were measured in 277 patients with a first and 72 patients with a recurrent VTE. All patients were categorized based on the quintiles of MP-TF and FVIII activity in those with a single VTE. For both markers, odds ratios (ORs) for recurrent VTE were computed using patients in the lowest quintile as a reference group. No association was observed between MP-TF activity and recurrent VTE, with an OR of 1.4 (95 % CI 0.7–2.9) in the highest quintile of MP-TF activity. Compared with the reference group, patients in the highest quintile of FVIII:C were at increased risk of recurrent VTE, OR 4.2 (95 % CI 1.4–12.2). MP-TF activity was not associated with recurrent VTE whereas high FVIII:C levels were associated with a 4-fold increased risk of VTE recurrence. Future prospective studies are necessary to explore the potential of FVIII:C as a tool for risk stratification, either by itself or in combination with other pro-thrombotic markers.

The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension

“…Zhang et al have shown TF involvement in the pathophysiological process of PTE, and that high levels of TF expression in pulmonary arterial tissue adjacent to emboli could lead to an increase in local coagulation activity [ 9 ]. Kooiman et al have also suggested that it is indispensable to assess the relationship between TF and acute/chronic thromboembolic disease [ 28 ].…”

Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review

“…After title and abstract screening, 64 studies were retrieved in full and reviewed, and 45 further studies were excluded due to duplicate study cohorts or ineligibility due to study design, study population, exposure, or outcome. Nineteen published studies were included in this review [ [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] ]. The study selection flow diagram is shown in Figure 1 [ 49 ].…”

“…[ 48 ] Prospective cohort 398 61 (median) 55 0 1.8 (median) 65 (16%) N/A Surgery, trauma, immobility, previous hospitalization, hormonal therapy, pregnancy, puerperium, active malignancy, thrombophilia (PC, PS, and AT deficiency) homozygous FVL, homozygous prothrombin mutation, and anticardiolipin antibodies or lupus anticoagulant Kooiman et al. [ 41 ] Case-control 349 54 (mean) 50 64 N/A 72 (21%) N/A Not reported Nagler et al. [ 42 ] Prospective cohort 479 58 (median) 50 45 4.6 (median) 101 (21%) N/A <3 Months from surgery, immobilization, long-distance travel, contraceptives, and pregnancy Kyrle et al.…”

Thrombophilic Evaluation in Patients with Acute Pulmonary Embolism

“…28,35 More recent work has suggested that tissue-factor bearing microparticles, the activity of which may have a hereditary component, are also associated with thrombosis risk. 36,37 Non-O blood type is also associated with higher VTE risk. 38,39 Several hereditary traits outside the coagulation system itself, including male gender, could be considered hereditary thrombophilias.…”